Pancreatic cancer

Programs in the registry with at least one linked ClinicalTrials.gov trial in pancreatic cancer (the trial's conditions or title mention it): 42 programs, 80 trials. Only confirmed (automatic) trial links are counted; each program's page has the rest.

Adenoviridae

Oncolytic

Ad5-yCD/mutTKSR39rep-hIL12 AXP000048

TrialTitlePhaseStatusStart
NCT03281382Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic CancerPhase 1Completed2017-07-01

CAdVEC AXP000042

TrialTitlePhaseStatusStart
NCT03740256Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPhase 1Recruiting2020-12-14

delolimogene mupadenorepvec AXP000007 · LOAd703, Oncolytic Adenovirus LOAd703

TrialTitlePhaseStatusStart
NCT03225989Trial Investigating an Immunostimulatory Oncolytic Adenovirus for CancerPhase 1/2Completed2018-03-01
NCT02705196LOAd703 Oncolytic Virus Therapy for Pancreatic CancerPhase 1/2Completed2016-11

H101 AXP000003 · Oncorine, Oncolytic Adenovirus H101, rAd5 H101

TrialTitlePhaseStatusStart
NCT06196671Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic CancerPhase 2Not yet recruiting2026-12-01
NCT05303090Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic CancerPhase 1Completed2022-03-31

MEM-288 AXP000041

TrialTitlePhaseStatusStart
NCT05076760MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPhase 1Recruiting2022-04-21

NG-350A AXP000038

TrialTitlePhaseStatusStart
NCT04787991Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaPhase 1Completed2021-08-09

zabilugene almadenorepvec AXP000008 · VCN-01

TrialTitlePhaseStatusStart
NCT07701486A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerPhase 1/2Recruiting2026-07-31
NCT05673811Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerPhase 2Completed2023-01-10
NCT05057715huCART-meso + VCN-01 in Pancreatic and Ovarian CancerPhase 1Terminated2022-03-02
NCT02045602Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid TumorsPhase 1Completed2014-01
NCT02045589A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic CancerPhase 1Completed2014-01

In vivo gene transfer

aglatimagene besadenovec AXP000144 · GliAtak, ProstAtak, Virafir

TrialTitlePhaseStatusStart
NCT02446093Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaPhase 2Unknown2015-10
NCT00638612AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)Phase 1Completed2008-08

golnerminogene pradenovec AXP000150 · TNFerade, ADgv EGR.TNF.11D

TrialTitlePhaseStatusStart
NCT00051467A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic CancerPhase 3Completed

Vaccine vector

ETBX-011 AXP000154

TrialTitlePhaseStatusStart
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccinePhase 2Withdrawn2018-08
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccinePhase 1/2Terminated2018-07-17
NCT03387098QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyPhase 1/2Terminated2017-12-28
NCT03329248QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyPhase 1/2Terminated2017-11-06
NCT03136406QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyPhase 1/2Terminated2017-08-11
NCT03127098QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerPhase 1/2Terminated2017-06-26

ETBX-021 AXP000155

TrialTitlePhaseStatusStart
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccinePhase 2Withdrawn2018-08
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccinePhase 1/2Terminated2018-07-17

ETBX-051 AXP000156

TrialTitlePhaseStatusStart
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccinePhase 2Withdrawn2018-08
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccinePhase 1/2Terminated2018-07-17

ETBX-061 AXP000157

TrialTitlePhaseStatusStart
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccinePhase 2Withdrawn2018-08
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccinePhase 1/2Terminated2018-07-17

GRT-C903 AXP000162

TrialTitlePhaseStatusStart
NCT03953235A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensPhase 1/2Completed2019-07-18

Orthoherpesviridae

Oncolytic

canerpaturev AXP000076 · HF10, TBI-1401, C-REV

TrialTitlePhaseStatusStart
NCT03252808Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.Phase 1Active not recruiting2017-09-25

OH2 AXP000089 · OH2 injection, oHSV2hGM-CSF

TrialTitlePhaseStatusStart
NCT04637698OH2 Oncolytic Viral Therapy in Pancreatic CancerPhase 1/2Terminated2021-02-02

OrienX010 AXP000077

TrialTitlePhaseStatusStart
NCT01935453A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat CancerPhase 1Completed2012-05

R130 AXP000091

TrialTitlePhaseStatusStart
NCT05886075A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid TumorsEarly phase 1Unknown2023-03-30
NCT05860374A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid TumorsEarly phase 1Unknown2023-03-02

STI-1386 AXP000135 · Seprehvec, Oncolytic HSV-1 STI-1386

TrialTitlePhaseStatusStart
NCT05361954Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid TumorsPhase 1Not yet recruiting2023-08

talimogene laherparepvec AXP000001 · Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC

TrialTitlePhaseStatusStart
NCT03086642Study of Talimogene Laherparepvec (T-VEC) in Pancreatic CancerPhase 1Completed2017-11-16
NCT00402025Talimogene Laherparepvec in Patients With Unresectable Pancreatic CancerPhase 1Completed2006-11

VG161 AXP000082 · Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)

TrialTitlePhaseStatusStart
NCT05162118Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerPhase 1/2Unknown2022-03-08

Parvoviridae

Oncolytic

ParvOryx AXP000127

TrialTitlePhaseStatusStart
NCT02653313Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic CancerPhase 1/2Completed2015-12

Poxviridae

Oncolytic

GC001 AXP000108

TrialTitlePhaseStatusStart
NCT06508307A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid TumorsPhase 1Recruiting2023-04-26

hV01 AXP000103 · Recombinant human IL-21-expressing oncolytic vaccinia virus injection

TrialTitlePhaseStatusStart
NCT07006077Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic CancerPhase 2Recruiting2025-05-29

IDOV-Immune AXP000110

TrialTitlePhaseStatusStart
NCT06910657IDOV-Immune for Advanced Solid TumorsPhase 1Recruiting2025-08-25

JX-929 AXP000097 · vvDD-CDSR

TrialTitlePhaseStatusStart
NCT00574977Safety Study of Modified Vaccinia Virus to CancerPhase 1Completed2008-05

Vaccine vector

CV301 AXP000180 · CV301-V/F, CVAC-301, FPV-CV301

TrialTitlePhaseStatusStart
NCT03376659Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaPhase 1/2Terminated2018-08-08

p53MVA AXP000187 · MVA-p53

TrialTitlePhaseStatusStart
NCT02432963Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyPhase 1Active not recruiting2015-12-28
NCT01191684Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic CancerPhase 1Completed2011-12-22

PANVAC AXP000179 · falimarev, inalimarev, PANVAC-F

TrialTitlePhaseStatusStart
NCT00669734Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryPhase 1Active not recruiting2010-02-01
NCT00088660PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing RegimenPhase 3Unknown2004-06

Retroviridae

Oncolytic

vocimagene amiretrorepvec AXP000126 · Toca 511

TrialTitlePhaseStatusStart
NCT02576665A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)Phase 1Terminated2016-07

In vivo gene transfer

Rexin-G AXP000210 · Mx-dnG1, DeltaRex-G, Retrovector Encoding Mutant Anti-Cyclin G1

TrialTitlePhaseStatusStart
NCT00504998Safety/Efficacy Study of Rexin-G to Treat Pancreatic CancerPhase 1/2Completed2007-07
NCT00121745Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic CancerPhase 1Terminated2005-07

Spinareoviridae

Oncolytic

pelareorep AXP000004 · Reolysin, PO-BB0209

TrialTitlePhaseStatusStart
NCT07280377A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabPhase 1/2Active not recruiting2021-10-27
NCT03723915Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerPhase 2Terminated2018-11-14
NCT02620423Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaPhase 1Completed2015-12
NCT01280058Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic CancerPhase 2Completed2010-12
NCT00998322A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic AdenocarcinomaPhase 2Completed2009-10

Togaviridae

Oncolytic

VRT106 AXP000128

TrialTitlePhaseStatusStart
NCT06758544A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerPhase 1/2Recruiting2025-03-17
NCT06866977A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic CancerPhase 1/2Not yet recruiting2025-03-12

Vaccine vector

AVX701 AXP000213 · CEA(6D) VRP

TrialTitlePhaseStatusStart
NCT00529984A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing MalignanciesPhase 1/2Completed2007-09

Targeted small molecule

adagrasib AXP000024 · Krazati, MRTX849

TrialTitlePhaseStatusStart
NCT06130254Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersPhase 1Terminated2024-01-30
NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 1Recruiting2023-10-18
NCT05634525Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer PatientsPhase 1Withdrawn2023-05-03

daraxonrasib AXP000027 · Rasonque, RMC-6236

TrialTitlePhaseStatusStart
NCT07898813Daraxonrasib in Resectable PDACPhase 1Not yet recruiting2027-04-13
NCT07895498A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic CancerPhase 2Recruiting2026-10-16
NCT07756281First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerPhase 1Recruiting2026-09-01
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPhase 3Recruiting2026-08-28
NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 3Recruiting2026-03-09
NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPhase 1Recruiting2026-01-08
NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Recruiting2025-12-15
NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/2Recruiting2025-05-31
NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Active not recruiting2024-10-16
NCT06360354A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Phase 1Active not recruiting2024-05-29
NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/2Recruiting2024-05-24
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/2Recruiting2023-11-14
NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1Recruiting2023-09-07
NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2Recruiting2022-05-31
NCT07573215Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaApproved for marketing

elironrasib AXP000028 · RMC-6291

TrialTitlePhaseStatusStart
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/2Recruiting2023-11-14
NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsPhase 1Active not recruiting2022-09-19

glecirasib AXP000030 · 艾瑞凯, JAB-21822

TrialTitlePhaseStatusStart
NCT06008288A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.Phase 2Recruiting2023-10-27
NCT05288205Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationPhase 1/2Recruiting2022-04-14

MRTX1133 AXP000026

TrialTitlePhaseStatusStart
NCT05737706Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationPhase 1Terminated2023-03-06

olomorasib AXP000032 · LY3537982

TrialTitlePhaseStatusStart
NCT04956640Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Phase 1/2Active not recruiting2021-07-19

sotorasib AXP000023 · Lumakras, Lumykras, AMG 510

TrialTitlePhaseStatusStart
NCT07563738A 2-part Phase 1/2 Open-label Trial on ODM-212Phase 1/2Recruiting2026-03-27
NCT06892054Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic AdenocarcinomaPhase 1Recruiting2025-08-08
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas CancerPhase 1/2Withdrawn2022-09-13

zoldonrasib AXP000029 · RM-036, RMC-9805

TrialTitlePhaseStatusStart
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPhase 3Recruiting2026-08-28
NCT07621718Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Phase 3Recruiting2026-05-22
NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/2Recruiting2025-05-31
NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/2Recruiting2024-05-24
NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1Recruiting2023-09-07